New developments in obesity

European Journal of Internal Medicine

Volumn 11, Issue 2, 2000, Pages 65-74

  Katsilambros, N ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Antiobesity drugs; Body fat distribution; Leptin; Obesity; Physical activity

Indexed keywords

ACARBOSE; AMFEPRAMONE; BETA 3 ADRENERGIC RECEPTOR STIMULATING AGENT; CAFFEINE; DEXFENFLURAMINE; EPHEDRINE; FLUOXETINE; GROWTH HORMONE; LEPTIN; MAZINDOL; PHENTERMINE; PHENYLPROPANOLAMINE; SIBUTRAMINE; TETRAHYDROLIPSTATIN; THYROID HORMONE;

BODY FAT; BROWN ADIPOSE TISSUE; COST; DIABETES MELLITUS; DIET; ENERGY EXPENDITURE; EXERCISE; GASTROINTESTINAL SYMPTOM; HORMONE RELEASE; HUMAN; LIFESTYLE; NEUROTOXICITY; OBESITY; PATHOPHYSIOLOGY; PREVALENCE; REVIEW; SIDE EFFECT; THERMOGENESIS; WEIGHT REDUCTION;

EID: 0034078661     PISSN: 09536205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0953-6205(00)00063-7     Document Type: Review

References (83)

1. Deurenberg P., Weststrate J.A., Seidell J.C. Body mass index as a measure of body fatness: age-and sex-specific prediction formulas. Br J Nutrition. 65:1991;105-114.
2. Seidell J.C., Flegal K.M. Assessing obesity: classification and epidemiology. Br Med Bull. 53:1997;238-252.
3. Wickelgreen I. Obesity: how big a problem? Science. 280:1998;1364-1367.
4. Rissanen A., Knecht P., Heliövaara M., Aromaa A., Reunanen A., Matela J. Weight and mortality in Finnish women. J Clin Epidemiol. 44:1991;787-795.
5. Sorensen H.T., Sabroe S., Gillman M., et al. Continued increase in prevalence of obesity in Danish young men. Int J Obes. 21:1997;712-714.
6. Lean M. Clinical handbook of weight management. 1998;Martin Dunitz, London.
7. Kalmijn S., Curb J.D., Rodriguez B.L., Yano K., Abbott R.D. The association of body weight and anthropometry with mortality in elderly men: The Honolulu Heart Program. Int J Obes. 23:1999;395-402.
8. Stevens J., Janwen C., Pamuk E.R., Williamson D.F., Thun M.J., Wood J.L. The effect of age on the association between body-mass index and mortality. New Engl J Med. 338:1998;1-7.
9. Hanson R.L., Jacobsson L.T.H., McCance D.R., et al. Weight fluctuation, mortality and vascular disease in Pima Indians. Int J Obes. 20:1996;463-471.
10. Narbro K., Jonsson E., Larsson B., Waaler H., Wedel H., Sjöström L. Economic consequences of sick-leave and early retirement in obese Swedish women. Int J Obes. 20:1996;895-903.
11. Ravoussin E., Lillioja S., Knowler W. Reduced rate of energy expenditure as a risk factor for body-weight gain. New Engl J Med. 318:1998;467-472.
12. Roberts S.B., Savage J., Coward W.A., Chew B., Lucas A. Energy expenditure and energy intake in infants born to lean and overweight mothers. New Engl J Med. 318:1998;466.
13. Ravussin E., Danforth Jr E. Beyond sloth-Physical activity and weight gain. Science. 283:1999;184-185.
14. Ravussin E., Gautier J.F. Metabolic predictors of weight gain. Int J Obes Relat Metab Disord. 23:(Suppl 1):1999;37-41.
15. Blaak E.E., van Blaak M.A., Kester A.D.M., Saris W.H.M. β-Adrenergically mediated thermogenic and heart responses: effect of obesity and weight loss. Metabolism. 44:1995;520-524.
16. Björntorp P. Visceral obesity: a 'Civilization Syndrome'. Obes Res. 1:1993;206-222.
17. Chroussos G.P., Gold B.W. The concepts of stress and stress system disorders. Overview of physical and behavioral homeostasis. J Am Med Assoc. 267:1992;1244-1252.
18. Björntorp P. The regulation of adipose tissue distribution in humans. Int J Obes. 20:1996;291-302.
19. Reaven G.M. Syndrome X: 6 years later. J Int Med. 236:(suppl):1994;13-22.
20. Janand-Delenne B., Chagnaud C., Raccah D., Alessi M.C., Juhan-Vague I., Vague P. Visceral fat as a main determinant of plasminogen activator inhibitor 1 level in women. Int J Obes. 22:1998;312-317.
21. Vague J. The degree of masculine differentiation of obesities. Am J Clin Nutr. 4:1956;20-34.
22. Larsson B., Svardsudd K., Welin L., et al. Abdominal adipose tissue distribution, obesity, and risk of cardiovascular disease and death. Br Med J. 288:1984;1401-1404.
23. Lapidus L., Bengtsson C., Larsson B., et al. Distribution of adipose tissue and risk of cardiovascular disease and death. Br Med J. 289:1984;1257-1261.
24. Björntorp P. Obesity and diabetes. Alberti K.G.M.M., Krall L.P. The diabetes annual/5. 1990;373-395 Elsevier, Amsterdam.
25. Kaplan N.M. The deadly quarter. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch Int Med. 149:1989;1514-1520.
26. Mantzoros C.S., Georgiodis E.I., Young R., et al. Relative androgenicity and blood pressure levels of young, healthy females. Am J Hypertens. 8:1995;606-614.
27. Katsilambros N., Georgiadis E., Aliferis C., et al. Serum lipids and arterial blood pressure in relation to waist-to-hip ratio in young males. Am J Clin Nutr. 57:1993;697-698.
28. Molarius A., Seidell J.C. Selection of anthropometric indicators for classification of abdominal fatness - a critical review. Int J Obes. 22:1998;719-722.
29. Molarius A., Seidell J.C., Sans S., Tuomilehto J., Kuulasmaa K. Waist and hip circumferences, and waist-hip ratio in 19 populations of the WHO MONICA Project. Int J Obes. 23:1999;116-125. For the WHO MONICA Project.
30. Lean M.E.J., Han T.S., Seidell J.C. Waist circumference indicates a larger burden of ill-health than Body Mass Index. Lancet. 351:1998;853-856.
31. Hall J.E. Mechanisms of abnormal renal sodium handling in obesity hypertension. Am J Hypertens. 10:1997;49-55.
32. Macdiarmid J.I., Vail A., Cade J.E., Blundell J.E. The sugar-fat relationship revisited: differences in consumption between men and women of varying BMI. Int J Obes. 22:1998;1053-1061.
33. Golay A., Bobbioni E. The role of dietary fat in obesity. Int J Obes. 21:(suppl.3):1997;s2-s11.
34. Blundell E.J., Burley J.V., Cotton R.J., Lawton L.C. Dietary fat and the control of energy intake: evaluating the effects of fat on meal size and post-meal satiety. Am J Clin Nutr. 57:(suppl):1993;7725-7785.
35. Dagogo-Jack S. Regulation and possible significance of leptin in humans: leptin in health and disease. Diabetes Rev. 7:1999;23-38.
36. Tritos N.A., Mantzoros C.S. Leptin: its role in obesity and beyond. Diabetologia. 40:1997;1371-1379. (review article).
37. Mantzoros CS. The role of leptin in human obesity and disease: a review of current evidence. 1999;130:671-80.
38. Stephens T.W., Basinski M., Bristow P.K., et al. The role of neuropeptide Y in the antiobesity action of the obese gene product. Nature. 377:1995;530-532.
39. Jockenhovel F., Blum W., Vogel E., et al. Testosterone substitution normalizes elevated serum leptin levels in hypogonadal men. J Clin Endocrinol Metab. 82:1997;2510-2513.
40. Lonnquist E., Acner P., Norillors L., Schalling M. Overexpression of the obese (ob) gene in adipose tissue of obese subjects. Nat Med. 1:1995;950-953.
41. Considine R.V., Sinha M.K., Heiman M.L., et al. Serum immunoreactive leptin concentrations in normal-weight and obese humans. New Engl J Med. 334:1996;292-295.
42. Caro J.F., Kolaczynski J.W., Nyce M.R., Ohannesian J.P., Opentanova I., Goldman W.H. Decreased cerebrospinal-fluid/serum leptin ratio in obesity: a possible mechanism for leptin resistance. Lancet. 348:1996;159-161.
43. Mantzoros C.S., Moschos S., Avramopoulos I., Kaklamani V., Liolios A., Doulgerakis D.E., et al. Leptin concentrations in relation to body mass index and the tumor necrosis factor-α system in humans. J Clin Endocrinol Metab. 82:1997;3408-3413.
44. Montague C.T., Farooqi I.S., Whitehead J.P., Soos M.A., Rau H., Wareham N.J. Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature. 387:1997;903-907.
45. Bouchard C., Perisse L. Genetics of obesity. Annu Rev Nutr. 354:1993;337-354.
46. Chua S., Leibel R.L. Obesity genes: molecular and metabolic mechanisms. Diabetes Rev. 5:1997;2-7.
47. Widen E., Lehto M., Kanninen T., Walston J., Shuldiner A.R., Groop L.C. Association of a polymorphism in the β3-adrenergic-receptor gene with features of the insulin resistance syndrome in Finns. New Engl J Med. 333:1995;348-351.
48. French S.A., Jeffery R.W., Sherwood N.E., Neumark-Sztainer D. Prevalence and correlates of binge eating in a nonclinical sample of women enrolled in a weight gain prevention program. Int J Obes. 23:1999;576-585.
49. Stunkard A., Berkowitz, Wadden T., Tanrikut C., Reiss E., Young L. Binge eating disorder and the night-eating syndrome. Int J Obes. 20:1996;1-6.
50. Allison D.B., Zannolli R., Faith M.S., et al. Weight loss increases and fat loss decreases all-cause mortality rate: results from two independent cohort studies. Int J Obes. 23:1999;603-611.
51. Karlsson J., Sjöström I., Sullivan M. Swedish obese subjects (SOS) - an intervention study of obesity. Two-year follow up of health-related quality of life (HRQL) and eating behavior after gastric surgery for severe obesity. Int J Obes. 22:1998;113-126.
52. Golditz G.A., Willett W.C., Rotnitzky A., Manson J.E. Weight loss significantly reduces the risk of developing Type II diabetes. Ann Intern Med. 122:1995;481-486.
53. Smith S.R., Zachwiefa J.J. Visceral adipose tissue: a critical review of intervention strategies. Int J Obes. 23:1999;329-335.
54. Summerbell C.D. Dietary treatment of obesity. Kopelman P.C., Stock M.J. Clinical obesity. 1998;377-408 Blackwell Science, London.
55. Brownwell K.D., Kramer F.M. Behavioral management of obesity. Med Clin North Am. 73:1989;185-201.
56. Perri M.C. Improving maintenance of weight loss following treatment by diet and lifestyle modification. Wadden T.A., Van Itallie T.B. Treatment of the seriously obese patient. 1992;456-477 Guilford Press, London.
57. Rössner S., Flaten H. VLCD versus LCD in long-term treatment of obesity. Int J Obes. 21:1997;22-26.
58. Barlow C.E., Kohl H.W., Gibson L.W., Blair S.N. Physical fitness, mortality and obesity. Int J Obes. 19:(Suppl. 4):1995;41-44.
59. Do Lee C., Blair N.S., Jackson A.S. Cardiorespiratory fitness, body composition and all-cause and cardiovascular disease mortality in men. Am J Clin Nutr. 69:1999;373-380.
60. Van Baak M.A., Saris W.H.M. Exercise and obesity. Kopelman P.C., Stock M.J. Clinical obesity. 1998;429-462 Blackwell Science, London.
61. Long term pharmacotherapy in the management of obesity. J Am Med Assoc. 276:1996;1907-1915.
62. Jung R.T. Drug treatment in obesity: general principles and current therapies. Kopelman P.C., Stock M.S. Clinical obesity. 1998;469-507 Blackwell Science, London.
63. Connolly H.M., Crary J.L., McCoon M.D., et al. Valvular heart disease associated with fenfluramine - phentermine. New Engl J Med. 337:1997;581-588.
64. Sjöström L., Rissanen A., Andersen T., et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet. 352:1998;162-167. For the European Multicentre Orlistat Study Group.
65. Finer N. Present and future pharmacological approaches. Br Med Bull. 53:1997;409-432.
66. Marcus M.D., Wing R.R., Ewing L., Kern E., McDermott M., Gooding W. A double blind placebo controlled trial of fluoxetine plus behavior modification in the treatment of obese binge-eaters and non-binge-eaters. Am J Psychiatry. 147:1990;876-881.
67. Darga L.L., Carroll-Michals L., Botsford S.L., Lucas C.P. Fluoxetine's effect on weight loss in obese subjects. Am J Clin Nutr. 54:1991;321-325.
68. Astrup A., Buemann B., Christensen N.J., et al. The effect of ephedrine/caffeine mixture on energy expenditure and body composition in obese women. Metabolism. 41:1992;686-688.
69. Carruba M., Tomello C., Briscini L., Nisoli E. Advances in pharmacotherapy for obesity. Int J Obes. 22:(Suppl):1998;s13-s16.
70. Greenberg AS, Heymsfield SB, Fujoka K. Preliminary safety and efficacy of recombinant methionyl human leptin administered by subcutaneous injection in lean and obese subjects [Abstract]. Program, 58th Annual Meeting, American Diabetes Association, 1998. Alexandria, VA: American Diabetes Association, 1998.
71. Van Gaal L.F., Wauters M.A., Mertens I.L., Considine R.V., DeLeeuw I.H. Clinical endocrinology of human leptin. Int J Obes. 23:(suppl 1):1999;29-36.
72. Kral J.G. Surgical treatment of obesity. Kopelman P.G., Stock M.J. Clinical obesity. 1998;545-563 Blackwell Science, London.
73. Kral J.G., Sjöström L.V., Sullivan M.B. Assessment of quality of life before and after surgery for severe obesity. Am J Clin Nutr. 55:(Suppl 2):1992;611S-614S.
74. Greenway F.L. Surgery for obesity. Endocrinol Metab Clin North Am. 25:(4):1996;1005-1027.
75. Mason E.E. Gastric surgery for morbid obesity. Surg Clin North Am. 72:(2):1992;501-513.
76. Terry B.E. Gastroplasty procedures, particularly vertical banded gastroplasty. Eur J Gastroenterol Hepatol. 11:1999;89-91.
77. Steffen R., Horber F., Hauri P. Swedish Adjustable Gastric Band (SAGB)-Distal Gastric Bypass: a new variant of an old technique in the treatment of superobesity and failed band operation. Obes Surg. 9:1999;171-176.
78. Johnson W.G., Hinkle L.K., Carr R.E., Anderson D.A., Lemmon C.R., Engler L.B., Bergeron K.C. Dietary and exercise interventions for juvenile obesity: long-term effect of behavioral and public health models. Obes Res. 5:(3):1997;257-261.
79. Glenny A.-M., O'Meara S., Melville A., Sheldon T.A., Wilson C. The treatment and prevention of obesity: a systematic review of the literature. Int J Obes. 21:1997;715-737.
80. Seidell J.C. Prevention of obesity: the role of the food industry. Nutr Metab Cardiovasc Dis. 9:1999;45-50.
81. Kristensen P., Judge M.E., Thim L., et al. Hypothalamic CART is a new anorectic peptide regulated by leptin. Nature. 393:1998;72-76.
82. Chambers J., Ames R.S., Bergsma D., et al. Melanin-concentrating hormone is the cognate ligand for the orphan G-protein-coupled receptor SLC-1. Nature. 400:1999;261-265.
83. Ricquier D. Recent developments on functions and regulations of the uncoupling proteins. Int J Obes. 23:(Suppl 5):1999;s9. (Abstract No 12).